1. |
World Health Organization. WHO coronavirus (COVID-19) dashboard[EB/OL]. [2021-12-04]. http://covid19.who.int.
|
2. |
|
3. |
|
4. |
|
5. |
|
6. |
|
7. |
|
8. |
|
9. |
|
10. |
|
11. |
|
12. |
|
13. |
Tanni SE, Fabro AT, de Albuquerque A, et al. Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Rev Respir Med. 2021 Jun;15(6): 791-803.
|
14. |
|
15. |
|
16. |
|
17. |
|
18. |
|
19. |
|
20. |
|
21. |
McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol, 2021, 320(2): L257-L265.
|
22. |
|
23. |
|
24. |
|
25. |
|
26. |
|
27. |
|
28. |
|
29. |
|
30. |
|
31. |
|
32. |
|
33. |
|
34. |
|
35. |
|
36. |
|
37. |
|
38. |
|
39. |
|
40. |
|
41. |
|
42. |
|
43. |
|
44. |
|
45. |
|
46. |
|
47. |
|
48. |
|
49. |
|
50. |
|
51. |
Kerget B, Cil G, Araz O, et al. When and how important is anti-fibrotic therapy in the post-COVID-19 period? Bratisl Lek Listy, 2022, 123(9): 6953-6958.
|
52. |
|
53. |
|
54. |
|
55. |
|
56. |
|
57. |
|
58. |
|
59. |
|
60. |
|
61. |
|
62. |
|
63. |
|